Cold Spring Harbor Laboratory  
Contact Us | Faculty & Staff Directory

Lloyd Trotman

Associate Professor
Ph.D., University of Zurich, 2001

Cancer modeling and treatment; Senescence and tumor progression; cancer visualization; PTEN regulation

email This email address is being protected from spambots. You need JavaScript enabled to view it. , phone (516) 367-5054

Trotman2013 The past thirty years have shown massive advances in understanding molecular cancer biology.Yet, for the vast majority of patients, the traditional approaches of surgery, radiation- or chemotherapy still represent the best hope for effective treatment. Our major problem is that we recognize cancer as a genetic disease, but do not know the nature and extent of genetic alterations that occur when our cells become cancerous, simply because we are not yet able to measure them. With tremendous advances in genome analysis and increased access to patient tumor samples we may soon be able to read the cancerous transition of genomes. But this
technological advance directly leads to the second major problem, the interpretation of all the genetic changes. Finally, it is not clear if understanding the mechanisms behind the disease will indeed lead to a cure.

Our major research focus is solving the interpretation problem. We therefore aim to generate the best models of cancer. Most recently, we have developed RapidCaP, the first mouse model for live visualization and sequencing of endogenous metastatic prostate cancer. With this system, we can validate spontaneous genetic alterations by introducing them up front into the model. We use RapidCaP together with clinicians to define the genetics of metastasis and therapy resistance, and to identify novel biomarkers for lethal prostate cancer.
Our second focus is to understand the cell biology of cancer initiation. We realized that partial loss of tumor suppressors (e.g. PTEN-haploinsufficiency) drives many cancers. Thus, we now define how tumor suppressors are activated, transported and degraded so we can interfere to restore or even maximize their output.


Please visit Lloyd's Lab home page.

Selected Publications

RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC. Cancer Discov. 2014 Mar;4(3):318-33. doi: 10.1158/2159-8290.CD-13-0346. Epub 2014 Jan 20.
PMID: 24444712 [PubMed - in process] Related citations Select item 24392697

Turning off AKT: PHLPP as a drug target. Newton AC, Trotman LC. Annu Rev Pharmacol Toxicol. 2014;54:537-58. doi: 10.1146/annurev-pharmtox-011112-140338. PMID: 24392697 [PubMed - in process] Related citations Select item 24379448

Prostate cancer genetic-susceptibility locus on chromosome 20q13 is amplified and coupled to androgen receptor-regulation in metastatic tumors. Labbé DP, Nowak DG, Deblois G, Lessard L, Giguère V, Trotman LC, Tremblay ML. Mol Cancer Res. 2014 Feb;12(2):184-9. doi: 10.1158/1541-7786.MCR-13-0477. Epub 2013 Dec 30. PMID: 24379448 [PubMed - in process] Related citations Select item 23578748

PTEN plasticity: how the taming of a lethal gene can go too far. Naguib A, Trotman LC. Trends Cell Biol. 2013 Aug;23(8):374-9. doi: 10.1016/j.tcb.2013.03.003. Epub 2013 Apr 9. Review.
PMID: 23578748 [PubMed - indexed for MEDLINE] Related citations